CITATION REPORT List of articles citing

Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system

DOI: 10.1006/taap.1996.8034 Toxicology and Applied Pharmacology, 1997, 142, 278-87.

Source: https://exaly.com/paper-pdf/28601729/citation-report.pdf

Version: 2024-04-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
289	Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. 1998 , 55, 1013-23		56
288	The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. 1998 , 783, 77-84		124
287	Do endogenous cannabinoids contribute to HIV-mediated immune failure?. 1998 , 4, 196-200		11
286	Cannabinoid receptors and immunity. 1998 , 19, 373-81		202
285	Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. <i>Journal of Neuroimmunology</i> , 1998 , 83, 124-32	3.5	57
284	Cannabinoid receptors and their endogenous agonists. 1998 , 38, 179-200		301
283	Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. 1998 , 102-103, 59-63		16
282	The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. 1998 , 95, 837	5-80	328
281	Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. 1998 , 12, 1035-44		846
280	Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. 1998 , 53, 676-83		95
279	Mesenteric vasodilation mediated by endothelial anandamide receptors. 1999 , 33, 429-34		230
278	Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. 1999 , 11, 691-9		72
277	Effects of cannabinoids on the immune system and central nervous system: therapeutic implications. 1999 , 12, 317-26		17
276	The effects of cannabinoids on the brain. 1999 , 58, 315-48		648
275	Inhibition of luteinizing hormone secretion by delta9-tetrahydrocannabinol in the ovariectomized rat: effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists. 1999 , 64, 664-	-71	9
274	Presence and functional regulation of cannabinoid receptors in immune cells. 1999 , 65, 637-44		60
273	Molecular Evolution of Proteins Involved in the Arachidonic Acid Cascade. 1999 , 273-284		

(2002-2000)

272	AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. 2000 , 67, 259-66		36
271	Delta(9)-tetrahydrocannabinol selectively increases aspartyl cathepsin D proteolytic activity and impairs lysozyme processing by macrophages. 2000 , 22, 373-81		7
270	Cannabinoid receptors and the regulation of immune response. 2000 , 108, 169-90		228
269	Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes. <i>Journal of Neuroimmunology</i> , 2000 , 110, 161-7	3.5	31
268	Role of the superior colliculus in the motor effects of cannabinoids and dopamine. 2000 , 853, 207-14		13
267	Activational role of cannabinoids on movement. European Journal of Pharmacology, 2000, 391, 269-74	5.3	154
266	Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. <i>European Journal of Pharmacology</i> , 2000 , 396, 141-9	5.3	418
265	Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. 2000 , 275, 605-12		297
264	Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. 2000 , 165, 373-80		187
263	Cannabinoids and pain. 2001 , 6, 74-9		32
262	Cannabinoids and neuroprotection. 2001 , 24, 29-51		73
261	Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. <i>European Journal of Pharmacology</i> , 2001 , 423, 235-41	5.3	66
2 60	Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. 2002 , 100, 627-34		217
259	Cannabinol enhancement of interleukin-2 (IL-2) expression by T cells is associated with an increase in IL-2 distal nuclear factor of activated T cell activity. 2002 , 61, 446-54		26
258	Pain and cannabinoids: science and evidence. 2002 , 9, 41-67		15
257	Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. <i>Advances in Experimental Medicine and Biology</i> , 2001 , 493, 223-8	3.6	13
- 57	Diology, 2001 , 493, 223-6		
256	Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 302, 451-65	4.7	119

254 Cannabinoid receptor genetics and behavior. 2002,

253	International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. 2002 , 54, 161-202	2011
252	Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. 2002, 290, 91-6	46
251	Molecular biology of cannabinoid receptors. 2002 , 66, 123-42	81
250	Endocannabinoids in the immune system and cancer. 2002 , 66, 319-32	89
249	Endocannabinoids in pain modulation. 2002 , 66, 235-42	55
248	Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. 2002 , 66, 243-56	148
247	Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. 2002 , 2, 69-82	255
246	Endocannabinoids and cannabinoid receptor genetics. 2002 , 66, 307-44	91
245	Cannabinoid analgesia. 2002 , 95, 127-35	147
244	Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. <i>Journal of Neuroimmunology</i> , 2002 , 133, 124-31	179
243	Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. 2002 , 121, 229-39	71
242	Endocannabinoids and related fatty acid derivatives in pain modulation. 2002 , 121, 159-72	92
241	Expression of the murine CB2 cannabinoid receptor using a recombinant Semliki Forest virus. 2003 , 65, 1931-42	10
240	The cannabinoid system and immune modulation. 2003 , 74, 486-96	378
239	CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. 2003 , 368, 352-9	16
238	Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. 2003 , 100, 10529-33	415
237	Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003 , 306, 1077-85	65

236	Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. 2004 , 75, 884-92		29
235	Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in nalle rats and in rat models of inflammatory and neuropathic pain. 2004 , 20, 2311-20		138
234	Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. 2004 , 23, 233-43		81
233	Cannabinoid signaling in glial cells. 2004 , 48, 267-77		187
232	Lymphocytes as a neural probe: potential for studying psychiatric disorders. 2004 , 28, 559-76		280
231	Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. 2004 , 75, 969-77		21
230	Experimental methods to study the role of the peripheral cannabinoid receptor in immune function. 2006 , 123, 19-40		3
229	Endocannabinoid Receptor Genetics and Marijuana Use. 2005,		
228	Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. 2005, 388, 465-73		52
227	Biosynthesis and purification of a hydrophobic peptide from transmembrane domains of G-protein-coupled CB2 receptor. 2005 , 65, 450-8		16
226	Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. <i>European Journal of Pharmacology</i> , 2005 , 520, 164-71	5.3	46
225	Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. <i>Toxicology and Applied Pharmacology</i> , 2005 , 205, 107-15	4.6	14
224	Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?. <i>Journal of Neuroimmunology</i> , 2005 , 166, 3-18	3.5	192
223	Arachidonic acid mediates non-capacitative calcium entry evoked by CB1-cannabinoid receptor activation in DDT1 MF-2 smooth muscle cells. 2005 , 205, 58-67		7
222	Cannabinoids and Herpesviruses. 2005 , 33-49		
221	Indirect CB2 receptor and mediator-dependent stimulation of human whole-blood neutrophils by exogenous and endogenous cannabinoids. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 315, 641-7	4.7	16
220	CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. 2005 , 102, 3093-8		419
219	From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases. 2005 , 4, 667-75		11

218	Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. 2005 , 137, 217-23		63
217	Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. 2005 , 48, 6386-92		38
216	Therapeutic potential of cannabinoid receptor agonists as analgesic agents. 2005, 14, 695-703		51
215	Effects on the immune system. 2005 , 385-423		70
214	Cannabinoids. 2005,		22
213	Marijuana and Cannabinoid Research. 2005,		
212	Endocannabinoid mechanisms of pain modulation. 2006 , 8, E693-708		169
211	Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. 2006 , 54, 231-46		123
210	Cannabinoid signalling. 2006 , 78, 549-63		304
209	Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. 2006 , 43, 2169-79		95
208	CB2 cannabinoid receptor mediation of antinociception. 2006 , 122, 36-42		138
207	Cannabinoids, immune system and cytokine network. 2006 , 12, 3135-46		66
206	Hu 210: a potent tool for investigations of the cannabinoid system. 2001 , 7, 131-45		37
205	Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. 2006 , 1074, 514-36		386
204	Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. 2006 , 283, 75-83		45
203	Nicotine and cannabinoids: parallels, contrasts and interactions. <i>Neuroscience and Biobehavioral Reviews</i> , 2006 , 30, 1161-81	9	83
202	Cannabinoid receptors and endocannabinoids: evidence for new players. 2006, 8, E298-306		164
201	Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila. <i>European Journal of Pharmacology</i> , 2006 , 532, 170-7	5.3	32

200	Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. 2006 , 1071, 10-23	618
199	Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2006 , 171, 110-9	31
198	Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. 2006 , 291, G364-71	134
197	NMR characterization of recombinant transmembrane protein CB2 fragment CB2(180-233). 2006 , 13, 335-42	9
196	Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336. 2006 , 281, 28143-51	20
195	Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 317, 820-9	33
194	Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. 2006 , 281, 14192-206	178
193	The expression of the peripheral cannabinoid receptor on cells of the immune system and non-Hodgkin's lymphomas. 2007 , 48, 1389-99	14
192	Canabinoides. 2007 , 533-551	
191	The role of the hippocampus in mediating emotional responses to nicotine and cannabinoids: a possible neural substrate for functional interactions. 2007 , 18, 375-89	36
190	Effects of Marijuana on the Lung and Immune Defenses. 2007 , 253-275	3
189	The expression of receptors for endocannabinoids in human and rodent skeletal muscle. 2007 , 364, 105-10	131
188	Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. 2007 , 203, 246-57	36
187	Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. 2007 , 80, 414-9	19
186	Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. 2007 , 7, 360-71	55
186 185		55 34
	modulate CXCL12-induced chemotaxis. 2007 , 7, 360-71	

182	Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. 2007 , 151, 1262-71		12
181	Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. <i>Journal of Neuroimmunology</i> , 2007 , 189, 17-22	3.5	51
180	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. <i>Bioorganic and Medicinal Chemistry</i> , 2008 , 16, 322-35	3.4	30
179	Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. 2008 , 1139, 450-7		92
178	Pharmacological Properties of Cannabinoid Receptors in the Avian Brain: Similarity of Rat and Chicken Cannabinoid1 Receptor Recognition Sites and Expression of Cannabinoid2 Receptor-Like Immunoreactivity in the Embryonic Chick Brain. 2008 , 88, 213-222		
177	Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. 2008 , 153, 271-6		21
176	The peripheral cannabinoid receptor knockout mice: an update. 2008, 153, 309-18		91
175	Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells. 2008 , 153, 1003-10		27
174	The endocannabinoid system in cancer-potential therapeutic target?. 2008, 18, 176-89		53
173	Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structuresa short review. <i>Pharmacology Biochemistry and Behavior</i> , 2008 , 90, 501-11	3.9	300
172	Anandamide and neutrophil function in patients with fibromyalgia. 2008, 33, 676-85		53
171	Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. 2008 , 433, 77-81		33
170	Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications. 2008 , 121, 98-104		28
169	Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. 2008 , 8, 159-72		46
168	Critical role of the endocannabinoid system in the regulation of food intake and energy metabolism, with phylogenetic, developmental, and pathophysiological implications. 2008 , 8, 220-30		45
167	Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. 2008 , 8, 187-204		77
166	Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol. 2008 , 83, 785-96		41
165	Drug Addiction. 2008,		4

(2010-2009)

164	Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. 2009 , 43, 325-9		28
163	Cannabinoid type 2 receptor as a target for chronic - pain. 2009 , 9, 11-25		49
162	Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. 2009 , 11, e3		250
161	The therapeutic potential of novel cannabinoid receptors. <i>Pharmacology & Therapeutics</i> , 2009 , 122, 83-9	9 6 3.9	55
160	Delta9-tetrahydrocannabinol and cannabidiol modulate mitogen-induced tryptophan degradation and neopterin formation in peripheral blood mononuclear cells in vitro. <i>Journal of Neuroimmunology</i> , 2009 , 207, 75-82	3.5	39
159	Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. <i>European Journal of Pharmacology</i> , 2009 , 607, 143-50	5.3	36
158	(Endo)cannabinoids mediate different Ca2+ entry mechanisms in human bronchial epithelial cells. 2009 , 380, 67-77		6
157	Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. <i>Psychopharmacology</i> , 2009 , 202, 569-78	4.7	87
156	Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. 2009 , 8, 519-30		171
155	Endocannabinoid signaling in microglial cells. <i>Neuropharmacology</i> , 2009 , 56 Suppl 1, 244-53	5.5	194
154	A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors. 2009 , 158, 1652-61		27
153	Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications. 2009 , 88, 335-69		57
152	Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 5475-82	3.4	4
151	1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-(B)-tetrahydrocannabinols: New selective ligands for the	3.4	11
	cannabinoid CB(2) receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 7809-15	<i>J</i>	
150	Cannabinoid CB(2) receptor. <i>Bioorganic and Medicinal Chemistry</i> , 2010 , 18, 7809-15 Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. 2010 , 58, 1017-2		358
150 149			35 ⁸ 79
	Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. 2010 , 58, 1017-25. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of	30	

146	Mechanism of cancer pain. 2010 , 10, 164-78		123
145	The cannabinoid 2 receptor as a potential therapeutic target for sepsis. 2010 , 10, 224-34		12
144	Opioids and cannabinoids interactions: involvement in pain management. 2010 , 11, 462-73		34
143	Non-invasive imaging of the type 2 cannabinoid receptor, focus on positron emission tomography. 2010 , 10, 1527-43		27
142	Cannabinoids and experimental models of multiple sclerosis. 2010 , 215, 647-57		30
141	Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine. 2010 , 18, 207-15		4
140	Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke. 2010 , 166, 252-62		37
139	Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. 2010 , 177, 187-96		80
138	Brain cannabinoid CBI eceptors modulate cocaine's actions in mice. 2011 , 14, 1160-6		304
137	The promise and dilemma of cannabinoid therapy: Lessons from animal studies of bone disease. 2011 , 8, 84-95		
136	Antinociceptive effect of intrathecal cannabinoid receptor agonist WIN 55,212-2 in a rat bone tumor pain model. 2011 , 493, 67-71		23
135	The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. 2011 , 5, 34		74
134	Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. 2011 , 5, 63		80
133	Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. 2011 , 433, 175-85		50
132	Scientific Opinion on the safety of hemp (Cannabis genus) for use as animal feed. 2011 , 9, 2011		25
131	Activation of cannabinoid receptors by the pentacyclic triterpene Hamyrin inhibits inflammatory and neuropathic persistent pain in mice. 2011 , 152, 1872-1887		88
130	Update on the role of cannabinoid receptors after ischemic stroke. <i>Mediators of Inflammation</i> , 2012 , 2012, 824093	4.3	30
129	Cannabis use and psychosis: theme introduction. 2012 , 18, 4991-8		17

128	Cannabinoid receptors 1 and 2 oppositely regulate epidermal permeability barrier status and differentiation. 2012 , 21, 688-93		28	
127	Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. 2012 , 32, 18259-68		92	
126	The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease. 2012 , 1, 224		7	
125	Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia. 2012 , 227, 313-26		31	
124	Stem Cells and Cancer Stem Cells, Volume 6. 2012 ,		2	
123	Regulation of Stem Cells by the Endocannabinoid System. 2012 , 345-352			
122	Cannabinoid-like anti-inflammatory compounds from flax fiber. 2012 , 17, 479-99		26	
121	Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. 2013 , 56, 8224-56		96	
120	Spicing things up: synthetic cannabinoids. <i>Psychopharmacology</i> , 2013 , 228, 525-40	4.7	191	
119	Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor. 2013 , 126, 616-24		37	
118	Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes. <i>Journal of NeuroImmune Pharmacology</i> , 2013 , 8, 323-32	6.9	28	
117	Developmental effects of cannabinoids on zebrafish larvae. 2013 , 10, 283-93		37	
116	The role of endocannabinoids in pain modulation. 2013 , 27, 64-80		56	
115	The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects. 2013 , 33, 246-64		22	
114	Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. 2013 , 76, 846-57		59	
113	Validating Antibodies to the Cannabinoid CB2 Receptor: Antibody Sensitivity Is Not Evidence of Antibody Specificity. 2014 , 62, 395-404		55	
112	Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. 2014 , 111, E5007-15		222	
111	Marijuana use and brain immune mechanisms. 2014 , 118, 199-230		19	

110	Neuroinflammation and Neurodegeneration. 2014,		5
109	Modulation of strain-specific differences in gene expression by cannabinoid type 2 receptor deficiency. 2014 , 94, 423-32		11
108	Novel approaches to the development of anti-sepsis drugs. 2014 , 9, 523-31		13
107	Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity. <i>Journal of NeuroImmune Pharmacology</i> , 2014 , 9, 544-57	6.9	6
106	Impact of Cannabis Use on the Development of Psychotic Disorders. 2014 , 1, 115-128		69
105	CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?. 2014 , 86, 430-7		159
104	Involvement of cannabinoid receptors in peripheral and spinal morphine analgesia. 2014 , 261, 23-42		37
103	Expression Analysis of CB2-GFP BAC Transgenic Mice. <i>PLoS ONE</i> , 2015 , 10, e0138986	3.7	32
102	Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. <i>Journal of NeuroImmune Pharmacology</i> , 2015 , 10, 193-203	6.9	58
101	Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model. 2015 , 25, 587-92		9
100	Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds. 2015 , 25, 581-6		11
99	Cannabinoids and Huntington disease. 2015, 61-97		2
98	CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain. 2015 , 88, 64-74		42
97	Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by B -Tetrahydrocannabinol. <i>Journal of NeuroImmune Pharmacology</i> , 2015 , 10, 344-55	6.9	9
96	Emerging therapeutic targets of sepsis-associated acute kidney injury. 2015 , 35, 38-54		27
95	Cannabinoid receptor 1 is a major mediator of renal fibrosis. 2015 , 88, 72-84		67
94	Endocannabinoids and the Immune System in Health and Disease. 2015 , 231, 185-211		56
93	Gene-specific disruption of endocannabinoid receptor 1 (cnr1a) by ethanol probably leads to the development of fetal alcohol spectrum disorder (FASD) phenotypes in Japanese rice fish (Oryzias latipes) embryogenesis. 2015 , 167, 90-100		4

Delayed, persistent, serotonin syndrome and ileus with multiple organ failure after 'Spice' ingestion. **2016**, 4, 109-113

91	Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion. 2016 , 6, 277-284		4
90	Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development. <i>PLoS ONE</i> , 2016 , 11, e0167240	3.7	10
89	[Acute Psychosis after Consumption of Synthetic Cannabinoids]. <i>Fortschritte Der Neurologie Psychiatrie</i> , 2016 , 84, 150-4	0.5	5
88	From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. <i>Physiological Reviews</i> , 2016 , 96, 1593-659	47.9	222
87	The basolateral amygdala Eminobutyric acidergic system in health and disease. <i>Journal of Neuroscience Research</i> , 2016 , 94, 548-67	4.4	85
86	Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB receptor antagonists/inverse agonists. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 5291-5301	3.4	12
85	Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 359, 310-318	4.7	24
84	The CB receptor and its role as a regulator of inflammation. <i>Cellular and Molecular Life Sciences</i> , 2016 , 73, 4449-4470	10.3	229
83	Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB and CB Cannabinoid Receptors. <i>Journal of NeuroImmune Pharmacology</i> , 2016 , 11, 669-679	6.9	5
82	Chemical Activation of Sensory TRP Channels. <i>Topics in Medicinal Chemistry</i> , 2016 , 73-113	0.4	6
81	The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 357, 145	- 4 ₽	43
80	Brain cannabinoid receptor 2: expression, function and modulation. <i>Acta Pharmacologica Sinica</i> , 2017 , 38, 312-316	8	99
79	Drugs of Abuse. 2017 , 661-678		2
78	Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor. <i>Pharmacological Research</i> , 2017 , 119, 391-403	10.2	22
77	Alterations of the hematologic cells in synthetic cannabinoid users. <i>Journal of Clinical Laboratory Analysis</i> , 2017 , 31,	3	10
76	Cannabinoids: A Group of Promising Neuroprotective Agents. 2017 , 321-339		1
75	Taste and Smell. <i>Topics in Medicinal Chemistry</i> , 2017 ,	0.4	1

74	Cannabinoid 2 receptor is a novel anti-inflammatory target in experimental proliferative vitreoretinopathy. <i>Neuropharmacology</i> , 2017 , 113, 627-638	5.5	15
73	The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology, 2017, 114, 156-167	5.5	48
72	Cannabinoids and the Cannabinoid Receptors: An Overview. 2017 , 553-563		4
71	Cannabidiol Reduces Leukemic Cell Size - But Is It Important?. Frontiers in Pharmacology, 2017 , 8, 144	5.6	20
70	Microglial Activation in the Pathogenesis of Huntington's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017 , 9, 193	5.3	62
69	Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. <i>Mediators of Inflammation</i> , 2017 , 2017, 4315412	4.3	15
68	Cannabinoid CB 2 Receptor. 2017 , 689-698		0
67	Is the Cannabinoid CB Receptor a Major Regulator of the Neuroinflammatory Axis of the Neurovascular Unit in Humans?. <i>Advances in Pharmacology</i> , 2017 , 80, 367-396	5.7	6
66	The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. <i>Psychopharmacology</i> , 2018 , 235, 1923-1932	4.7	107
65	Dorsal hippocampal cannabinergic and GABAergic systems modulate memory consolidation in passive avoidance task. <i>Brain Research Bulletin</i> , 2018 , 137, 197-203	3.9	6
64	Electroacupuncture potentiates peripheral CB2 receptor-inhibited chronic pain in a mouse model of knee osteoarthritis. <i>Journal of Pain Research</i> , 2018 , 11, 2797-2808	2.9	15
63	Therapeutic applications of cannabinoids. <i>Chemico-Biological Interactions</i> , 2018 , 293, 77-88	5	39
62	Role for Endocannabinoids in Spinal Manipulative Therapy Analgesia?. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019 , 2019, 2878352	2.3	
61	Contrasting Roles of Cannabidiol as an Insecticide and Rescuing Agent for Ethanol-induced Death in the Tobacco Hornworm Manduca sexta. <i>Scientific Reports</i> , 2019 , 9, 10481	4.9	6
60	Modest and nonessential roles of the endocannabinoid system in immature hematopoiesis of mice. <i>Experimental Hematology</i> , 2019 , 78, 35-45	3.1	
59	A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics. <i>Pharmacology & Therapeutics</i> , 2019 , 201, 25-38	13.9	36
58	CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain. <i>Scientific Reports</i> , 2019 , 9, 7468	4.9	18
57	Prediction of Orthosteric and Allosteric Regulations on Cannabinoid Receptors Using Supervised Machine Learning Classifiers. <i>Molecular Pharmaceutics</i> , 2019 , 16, 2605-2615	5.6	19

(2021-2019)

56	Mechanisms of cannabinoid CB receptor-mediated reduction of dopamine neuronal excitability in mouse ventral tegmental area. <i>EBioMedicine</i> , 2019 , 42, 225-237	8.8	23
55	Cannabis-based medicines for chronic pain management: current and future prospects. <i>Current Opinion in Anaesthesiology</i> , 2019 , 32, 623-628	2.9	7
54	Pharmacological Interventions in Acute Kidney Injury. 2019 , 725-738.e13		
53	Progress in brain cannabinoid CB receptor research: From genes to behavior. <i>Neuroscience and Biobehavioral Reviews</i> , 2019 , 98, 208-220	9	88
52	Possible interaction between the ventral hippocampal cannabinoid CB2 and muscarinic acetylcholine receptors on the modulation of memory consolidation in mice. <i>NeuroReport</i> , 2020 , 31, 17	4 ⁻¹ 783	2
51	The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders. <i>Acta Pharmacologica Sinica</i> , 2020 , 41, 1507-1518	8	5
50	Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. <i>Pharmacology Biochemistry and Behavior</i> , 2020 , 199, 173059	3.9	13
49	Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions. <i>Adolescent Health, Medicine and Therapeutics</i> , 2020 , 11, 53-61	2.7	4
48	Long-Term Low-Dose Delta-9-Tetrahydrocannbinol (THC) Administration to Simian Immunodeficiency Virus (SIV) Infected Rhesus Macaques Stimulates the Release of Bioactive Blood Extracellular Vesicles (EVs) that Induce Divergent Structural Adaptations and Signaling Cues. <i>Cells</i> ,	7.9	0
47	2020, 9, Cannabinoid CB Receptor Activation Attenuates Fentanyl-Induced Respiratory Depression. Cannabis and Cannabinoid Research, 2021, 6, 389-400	4.6	3
46	THC Regulates Tearing via Cannabinoid CB1 Receptors. 2020 , 61, 48		3
45	Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder. <i>Journal of NeuroImmune Pharmacology</i> , 2020 , 15, 780-793	6.9	13
44	Shifting the Paradigm on Cannabis Safety. Cannabis and Cannabinoid Research, 2020,	4.6	2
43	Neuroprotection Following Concussion: The Potential Role for Cannabidiol. <i>Canadian Journal of Neurological Sciences</i> , 2020 , 47, 289-300	1	4
42	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease. <i>Molecules</i> , 2020 , 25,	4.8	14
41	Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders. <i>Frontiers in Pharmacology</i> , 2020 , 11, 618065	5.6	5
40	NSAIDs, Opioids, and Beyond.		
39	Endocannabinoid system: Role in blood cell development, neuroimmune interactions and associated disorders. <i>Journal of Neuroimmunology</i> , 2021 , 353, 577501	3.5	2

38	The Neuroprotective Properties, Functions, and Roles of Cannabis sativa in Selected Diseases Related to the Nervous System. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2021 , 21, 20-38	1.8	
37	Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. <i>Pharmacology Biochemistry and Behavior</i> , 2021 , 206, 173192	3.9	3
36	Cannabinoid receptor 2 deletion influences social memory and synaptic architecture in the hippocampus. <i>Scientific Reports</i> , 2021 , 11, 16828	4.9	2
35	Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry.		O
34	Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CBR modulators in neurodegenerative diseases. <i>Pharmacological Research</i> , 2021 , 170, 105607	10.2	2
33	The CB Receptor as a Novel Therapeutic Target for Epilepsy Treatment. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	4
32	Cannabinoid Modulation of Dopaminergic Circuits in Neurodegenerative and Neuropsychiatric Disorders. 2013 , 73-101		1
31	Cannabinoid receptors and the cytokine network. <i>Advances in Experimental Medicine and Biology</i> , 1998 , 437, 215-22	3.6	21
30	Neuromolecular Mechanisms of Cannabis Action. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1264, 15-28	3.6	3
29	PET Imaging of Endocannabinoid System. 2014, 249-319		5
29	PET Imaging of Endocannabinoid System. 2014 , 249-319 Pharmacology of Endocannabinoids and Their Receptors. 2020 , 415-445		2
		5-3	
28	Pharmacology of Endocannabinoids and Their Receptors. 2020 , 415-445 The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. <i>European</i>	5.3	2
28	Pharmacology of Endocannabinoids and Their Receptors. 2020, 415-445 The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. European Journal of Pharmacology, 2020, 886, 173544 Chronic Temporomandibular Joint Arthralgia. Oral and Maxillofacial Surgery Clinics of North America		2 14
28 27 26	Pharmacology of Endocannabinoids and Their Receptors. 2020, 415-445 The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. European Journal of Pharmacology, 2020, 886, 173544 Chronic Temporomandibular Joint Arthralgia. Oral and Maxillofacial Surgery Clinics of North America, 2000, 12, 5-26		2 14 6
28 27 26 25	Pharmacology of Endocannabinoids and Their Receptors. 2020, 415-445 The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. European Journal of Pharmacology, 2020, 886, 173544 Chronic Temporomandibular Joint Arthralgia. Oral and Maxillofacial Surgery Clinics of North America, 2000, 12, 5-26 Cannabinoid receptors and endocannabinoids: Evidence for new players. 2006, 8, E298 Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and	3.4	2 14 6 118
28 27 26 25 24	Pharmacology of Endocannabinoids and Their Receptors. 2020, 415-445 The cannabinoid CB receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence. European Journal of Pharmacology, 2020, 886, 173544 Chronic Temporomandibular Joint Arthralgia. Oral and Maxillofacial Surgery Clinics of North America, 2000, 12, 5-26 Cannabinoid receptors and endocannabinoids: Evidence for new players. 2006, 8, E298 Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. PLoS ONE, 2014, 9, e109115 CB2 Receptor in Microglia: The Guardian of Self-Control. International Journal of Molecular Sciences,	3.4	2 14 6 118 51

20 Endocannabinoid Mechanisms of Pain Modulation. 2008, 737-764

19	Therapeutic Potential of Cannabinoids. 2014 , 569-587		1
18	Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling. <i>PeerJ</i> , 2015 , 3, e1056	3.1	1
17	PET Imaging of the Endocannabinoid System. 2021 , 319-426		O
16	New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
15	Anti-Inflammatory and Pro-Autophagy Effects of the Cannabinoid Receptor CB2R: Possibility of Modulation in Type 1 Diabetes <i>Frontiers in Pharmacology</i> , 2021 , 12, 809965	5.6	O
14	Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects <i>Molecules</i> , 2022 , 27,	4.8	1
13	The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation <i>Frontiers in Pharmacology</i> , 2021 , 12, 806417	5.6	1
12	Receptor mechanisms underlying the CNS effects of cannabinoids: CB receptor and beyond <i>Advances in Pharmacology</i> , 2022 , 93, 275-333	5.7	1
11	Curcumae Longae Rhizoma and Saussureae Radix Inhibit Nitric Oxide Production and Cannabinoid Receptor 2 Down-regulation <i>In Vivo</i> , 2022 , 36, 227-232	2.3	O
10	Medicinal Cannabis and Central Nervous System Disorders Frontiers in Pharmacology, 2022 , 13, 88181	0 5.6	О
9	Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. <i>Frontiers in Psychiatry</i> , 13,	5	O
8	Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia. <i>CNS Drugs</i> ,	6.7	2
7	Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. 16,		
6	Endocannabinoid signaling in the central nervous system.		O
5	Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy.		1
4	Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential. 2022 , 10, 3000		O
3	Acute Ischemic Stroke Among Cannabis Users in the United States and Possible Risk Factors for Mortality. Publish Ahead of Print,		0

2 Update on the controversial identity of cells expressing cnr2 gene in the nervous system.

Ο

Cannabinoid Mixture Affects the Fate and Functions of B Cells through the Modulation of the Caspase and MAP Kinase Pathways. **2023**, 12, 588

О